ProFunds Biotechnology UltraSector Fund Investor Class BIPIX:NASDAQ

Net Asset Value$75.69Previous Close - 7/14/2020
1-Day Change+2.43(3.32%)
YTD Change+13.50(21.71%)

Growth of $10,000 Since Fund Inception

View portfolioPortfolio as of 04/30/2020

Top 5 SectorsTop 5 Holdings
Health Technology67.88%
Amgen Inc ORD11.83%
Health Services2.43%
Abbvie Inc ORD10.12%
Commercial Services1.10%
Gilead Sciences Inc ORD8.85%
Process Industries0.31%
Vertex Pharmaceuticals Inc ORD5.38%
Other0.04%
Biogen Inc ORD4.46%
Concentration of Top 571.76% Concentration of Top 540.64% 

Fund Profile

Fund Strategy

The Fund seeks daily investment results, before fees and expenses, that correspond to one and one-half times (1.5x) the daily performance of the Dow Jones U.S. Biotechnology Index for a single day. The Index seeks to measure the performance of certain companies in the biotechnology sector of the U.S. equity market.

Fund Category Sector Equity
Inception Date 06/19/2000
Manager Neches/Dave
Fund Classification Equity Leverage Funds
Managed Since 2013
Other Managed Funds   ROM  UYG  BIB  INPIX  ONLN

Lipper Leader Scorecard as of 06/30/2020

RatingTotal
Return
Consistent
Return
PreservationTax
Efficiency
Expense*
Overall Rating(# of funds in category)
177

173

12,306

177

42
3 Year Rating(# of funds in category)
177

175

12,306

177

42
5 Year Rating(# of funds in category)
165

163

10,510

165

41
10 Year Rating(# of funds in category)
133

133

7,095

133

39

Fund Highlights

Total Expense Ratio1.52%
Average Market Capitallization$71.7 B
Net Asset ValueN/A
Total Net Assets$189.6 M
Sales ExpensesNo Load Fund
Minimum Initial Investment$15000
Minimum IRA Investment$15000
AvailabilityOpen to New Investors
Current Yield0.00%
Dividend Ex-DateN/A

Risk Analysis

Beta vs. S&P 5001.26
R-Squared vs. S&P 5000.47
Standard Deviation31.53%
Sharpe Ratio0.57
Portfolio TurnoverN/A